Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Paediatr ; 101(11): 1151-5, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22834689

ABSTRACT

AIM: In a recent Swedish study, comparing data from the Swedish Cancer Register with the Medical Birth Register including data on IVF, an increased risk of Langerhans cell histiocytosis (LCH) was found in children born 1982-2005 after IVF. Here, we aimed to verify the LCH diagnoses and examine whether any special forms of the disease were overrepresented in this population. METHODS: Medical records for all children with LCH conceived by IVF were acquired and the diagnosis confirmed or discarded. Disease characteristics were compared with data from children diagnosed with LCH 1992-2001 in the Stockholm County. RESULTS: We verified LCH in seven children born after IVF, all born prior to 2002. These children did not have milder disease forms. The odds ratio (OR) to develop LCH for the whole group born after IVF was 3.2 [95% confidence interval (CI), 1.4-7.3] and for children born before 2002, 5.2 [95% CI, 2.3-11.9], compared with children in Stockholm County 1992-2001. CONCLUSION: LCH was overrepresented in children born after IVF prior to 2002. Affected children did not have milder disease forms. These findings may be valuable to understand LCH aetiology. Additional studies on a putative correlation between IVF and LCH in the offspring are encouraged.


Subject(s)
Fertilization in Vitro/adverse effects , Histiocytosis, Langerhans-Cell/etiology , Child, Preschool , Female , Histiocytosis, Langerhans-Cell/diagnosis , Histiocytosis, Langerhans-Cell/epidemiology , Humans , Male , Odds Ratio , Registries , Risk Factors , Sweden/epidemiology
2.
Acta Paediatr ; 100(7): e36-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21166862

ABSTRACT

AIM: There is currently no well-accepted therapy for central nervous system Langerhans cell histiocytosis (CNS-LCH), a neuroinflammatory disease clinically characterized by often progressive, neurological symptoms including ataxia, dysarthria, dysphagia, hypertonicity, intellectual impairment and behavioural abnormalities. We applied immunomodulative/anti-inflammatory treatment on a patient with progressive CNS-LCH disease. METHOD: Intravenous immunoglobulin (IVIG) was administered monthly for 15 years to a patient with severe, image-verified neurodegenerative CNS-LCH. RESULTS: During the IVIG treatment, the neurological deterioration initially appeared to be haltered, but over time there was still some deterioration. CONCLUSIONS: IVIG may be beneficial in partly haltering CNS-LCH neurodegeneration, but further studies are needed.


Subject(s)
Central Nervous System Diseases/drug therapy , Histiocytosis, Langerhans-Cell/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Adolescent , Child , Child, Preschool , Disease Progression , Follow-Up Studies , Humans , Infant , Male , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...